Graham JM Jr. The association between limb anomalies and spatially-restricting uterine environments. Prog Clin Biol Res 1985;163C:99–103.
77.
Romero R, Chervenak FA, DeVore G, et al. Fetal head deformation and congenital torticollis associated with a uterine tumor. Am J Obstet Gynecol 1981;141:839–840.
78.
Palerme GR, Friedman EA. Rupture of the gravid uterus in the third trimester. Am J Obstet Gynecol 1966;94:571–576.
79.
Garnet J. Uterine rupture during pregnancy. An analysis of 133 patients. Obstet Gynecol 1964;23:898–905.
80.
Obed J, Omigbodun A. Rupture of the uterus in patients with previous myomectomy and primary caesarean section scars: a comparison. J Obstet Gynaecol 1996;1:1621.
81.
Parker W, Einarsson J, Istre O, et al. Risk factors for uterine rupture following laparoscopic myomectomy. J Minim Invasive Gynecol 2010;17:551–554.
82.
Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005;308:1589–1592.
83.
Myers ER, Barber MD, Gustilo-Ashby T, et al. Management of uterine leiomyomata: what do we really know? Obstet Gynecol 2002;100:8–17.
84.
Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 2007;87:725–736.
85.
Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women’s Health Study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. Obstet Gynecol 1994;83:566–572.
86.
Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol 1986;68:10–12.
87.
Schlaff WD, Zerhouni EA, Huth JA, et al. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue leuprolide in the treatment of uterine leiomyomata. Obstet Gynecol 1989;74:856–862.
88.
Friedman AJ, Hoffman DI, Comite F, et al. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol 1991;77:720–725.
89.
Letterie GS, Coddington CC, Winkel CA, et al. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up. Fertil Steril 1989;51:951– 956.
90.
Leather AT, Studd JW, Watson NR, et al. The prevention of bone loss in young women treated with GnRH analogues with “add-back” estrogen therapy. Obstet Gynecol 1993;81:104–107.
91.